XML 47 R34.htm IDEA: XBRL DOCUMENT
v3.8.0.1

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Schedule of Stock Grants Activity | The following tables present a summary of the status of the grants to employees, officers and directors as of December 31, 2017, 2016 and 2015:
|  | Number |  |  | Weighted average exercise price (US$) |
Balance outstanding as of December 31,2014 |  |  | 450,847 |  |  |  | 5.85 |
Exercised during 2015 |  |  | (19,769 | ) |  |  | 1.82 |
Forfeited during 2015 |  |  | (17,605 | ) |  |  | 6.01 |
Balance outstanding as of December 31,2015 |  |  | 413,473 |  |  |  | 6.04 |
Balance exercisable as of December 31,2015 |  |  | 293,736 |  |  |  | 5.95 |
Granted during 2016 |  |  | 149,330 |  |  |  | 4.53 |
Balance outstanding as of December 31,2016 |  |  | 562,803 |  |  |  | 5.64 |
Balance exercisable as of December 31,2016 |  |  | 334,735 |  |  |  | 5.81 |
Granted during 2017 |  |  | 4,740,318 |  |  |  | 5.22 |
Forfeited during 2017 |  |  | (66,154 | ) |  |  | 3.93 |
Balance outstanding as of December 31,2017 |  |  | 5,236,967 |  |  |  | 5.28 |
Balance exercisable of December 31,2017 |  |  | 2,428,716 |  |  |  | 5.28 |
Schedule of Stock Grants, by Exercise Price Range | The following tables summarize information about options outstanding at December 31, 2017:
Exercise price (US$) |  |  | Outstanding at December 31, 2017 |  |  | Weighted average remaining contractual life (years) |  |  | Exercise price (US$) |  |  | Exercisable at December 31, 2017 |  |  | Weighted average remaining contractual life (years) |
| 6.25 |  |  |  | 351,712 |  |  |  | 4.19 |  |  |  | 6.25 |  |  |  | 351,712 |  |  |  | 4.19 |
| 6.02 |  |  |  | 4,273 |  |  |  | 0.03 |  |  |  | 6.02 |  |  |  | 4,273 |  |  |  | 0.03 |
| 7.00 |  |  |  | 22,000 |  |  |  | 6.50 |  |  |  | 7.00 |  |  |  | 22,000 |  |  |  | 6.50 |
| 4.75 |  |  |  | 12,000 |  |  |  | 8.01 |  |  |  | 4.75 |  |  |  | 12,000 |  |  |  | 8.01 |
| 4.50 |  |  |  | 79,998 |  |  |  | 8.21 |  |  |  | 4.50 |  |  |  | 79,998 |  |  |  | 8.21 |
| 4.50 |  |  |  | 26,666 |  |  |  | 8.88 |  |  |  | 4.50 |  |  |  | 22,793 |  |  |  | 8.88 |
| 4.50 |  |  |  | 1,673,996 |  |  |  | 9.21 |  |  |  | 4.50 |  |  |  | 1,231,016 |  |  |  | 9.21 |
| 5.41 |  |  |  | 559,414 |  |  |  | 9.21 |  |  |  | 5.41 |  |  |  | 0 |  |  |  | 0 |
| 7.75 |  |  |  | 844,130 |  |  |  | 9.21 |  |  |  | 7.75 |  |  |  | 0 |  |  |  | 0 |
| 4.50 |  |  |  | 661,875 |  |  |  | 9.26 |  |  |  | 4.50 |  |  |  | 304,615 |  |  |  | 9.26 |
| 7.75 |  |  |  | 50,000 |  |  |  | 9.26 |  |  |  | 7.75 |  |  |  | 16,667 |  |  |  | 9.26 |
| 4.50 |  |  |  | 74,470 |  |  |  | 9.41 |  |  |  | 4.50 |  |  |  | 65,709 |  |  |  | 9.41 |
| 4.50 |  |  |  | 290,585 |  |  |  | 9.48 |  |  |  | 4.50 |  |  |  | 140,660 |  |  |  | 9.48 |
| 4.50 |  |  |  | 585,848 |  |  |  | 9.71 |  |  |  | 4.50 |  |  |  | 177,273 |  |  |  | 9.71 |
|  |  |  |  | 5,236,967 |  |  |  |  |  |  |  |  |  |  |  | 2,428,716 |  |  |  |  |
Schedule of Assumptions Used to Value Options | The fair value of options granted to employees was estimated at the dates of grant using the Black-Scholes option pricing model. The following are the data and assumptions used:
|  | 2017 |  |  | 2016 |
Dividend yield (%) |  |  | 0 |  |  |  | 0 |
Expected volatility (%) (*) |  |  | 56.59 |  |  |  | 62.16 |
Risk free interest rate (%) |  |  | 0.92 |  |  |  | 1.08 |
Expected term of options (years) |  |  | 5-10.5 |  |  |  | 6 |
Exercise price (US dollars) |  |  | 4.50 - 7.75 |  |  |  | 4.50, 4.75 |
Stock price (US dollars) (**) |  |  | 2.38 |  |  |  | 2.38 |
Fair value (US dollars) |  |  | 0.58-1.28 |  |  |  | 1.01, 098 |
| (*) | Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on a sample of 254 companies operating in the Healthcare Products industry.
| (**) | The Common Stock price, per share for the year ended December 31, 2017 and 2016 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2017, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2016 Offering. In reaching its estimation for December 31, 2017, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units.
Series C Preferred Stock [Member] |
Schedule of Fair Value Assumptions | As of December 31, 2017, and 2016, The key inputs used in the fair value calculations of the Series C preferred warrant that were affected by the down-round protection were as follows:
|  | December 31, 2017 |  |  | December 31, 2016 |
Dividend yield (%) |  |  | - |  |  |  | - |
Expected volatility (%) |  |  | 56.59 |  |  |  | 56.59 |
Risk free interest rate (%) |  |  | 1.31 |  |  |  | 0.92 |
Expected term of options (years) |  |  | 3.27 - 4.58 |  |  |  | 4.27 - 4.92 |
Exercise price (US dollars) |  |  | 4.50, 7.75 |  |  |  | 4.50, 7.75 |
Share price (US dollars) |  |  | 2.45 |  |  |  | 2.38 |
Fair value (US dollars) |  |  | 0.29 - 0.76 |  |  |  | 0.39 – 0.75 |
Series D Preferred Stock [Member] |
Schedule of Fair Value Assumptions | As of December 31, 2017, the key inputs used in the fair value calculations of the Series D preferred warrant that were affected by the down-round protection were as follows:
|  | December 31, 2017 |
Dividend yield (%) |  |  | - |
Expected volatility (%) |  |  | 56.59 |
Risk free interest rate (%) |  |  | 1.31 |
Expected term of options (years) |  |  | 4.92 |
Exercise price (US dollars) |  |  | 4.50, 5.75, 7.75 |
Share price (US dollars) |  |  | 2.45 |
Fair value (US dollars) |  |  | 0.81, 0.66, 0.5 |
Derivative Warrant Liability [Member] |
Schedule of Changes in Fair Value of Level 3 Liability | The changes in the fair value of the Level 3 liability are as follows (in US dollars):
|  | Warrants with Down-Round Protection |
|  | December 31, |
|  | 2017 |  |  | 2016 |
Balance, Beginning of the year |  |  | 681,970 |  |  |  | 321,695 |
Warrants issued as consideration for placement services |  |  | 353,721 |  |  |  | 308,239 |
Stock based compensation to financial advisor |  |  | 32,880 |  |  |  | - |
Amount classified out of stockholders’ deficit and presented as Warrants with Down-Round Protection |  |  | - |  |  |  | 341,662 |
Change in fair value of Warrants with Down-Round Protection |  |  | (300,322 | ) |  |  | (289,626 | )
Balance, End of year |  |  | 768,249 |  |  |  | 681,970 |
Schedule of Fair Value Assumptions | The key inputs used in the fair value calculations were as follows:
|  | December 31, 2017 |  |  | December 31, 2016 |
Dividend yield (%) |  |  | - |  |  |  | - |
Expected volatility (%) (*) |  |  | 56.59 |  |  |  | 56.59 |
Risk free interest rate (%) |  |  | 1.31 |  |  |  | 0.92 |
Expected term of options (years) |  |  | 0.2 - 4.92 |  |  |  | 1.20 - 4.92 |
Exercise price (US dollars) |  |  | 4.50 – 7.75 |  |  |  | 4.50 - 7.75 |
Share price (US dollars) (**) |  |  | 2.45 |  |  |  | 2.38 |
Fair value (US dollars) (***) |  |  | 0.002 - 0.81 |  |  |  | 0.16 – 0.75 |
| (*) | Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on a sample of 254 companies operating in the Healthcare Products industry.
| (**) | The Common Stock price, per share reflects the Company’s management’s estimation of the fair value per share of Common Stock as of December 31, 2017, and 2016. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units at December 31, 2017, as applicable to each reporting period.
(***) The below chart reflects the Fair Value for each of the Warrants with down-round Protection that were outstanding as of December 31, 2017 in US dollars.
|  | Investors |  |  | AGI - Series A |  |  | AGI - Series B |  |  | AGI - Series C |  |  | AGI - Series D |
Total quantity |  |  | 126,935 |  |  |  | 364,071 |  |  |  | 566,897 |  |  |  | 844,605 |  |  |  | 37,777 |
Exercise price |  |  | 4.5 |  |  |  | 4.5 |  |  |  | 4.5, 7.75 |  |  |  | 4.5, 7.75 |  |  |  | 4.5 5.75, 7.75 |
Fair value |  |  | 0.31 |  |  |  | 0.12 |  |  |  | 0.12 – 0.34 |  |  |  | 0.29 – 0.76 |  |  |  | 0.5 – 0.81 |
Warrant [Member] |
Schedule of Fair Value Assumptions | As of December 31, 2017 and 2016, The key inputs used in the fair value calculations of the Series A preferred warrant that were affected by the down-round protection were as follows:
|  | December 31, 2017 |  |  | December 31, 2016 |
|  | Investors |  |  | Placement agent |  |  | Investors |  |  | Placement agent |
Dividend yield (%) |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |
Expected volatility (%) |  |  | 56.69 |  |  |  | 56.69 |  |  |  | 56.69 |  |  |  | 56.69 |
Risk free interest rate (%) |  |  | 1.31 |  |  |  | 1.31 |  |  |  | 0.92 |  |  |  | 0.92 |
Expected term of options (years) |  |  | 0.2 |  |  |  | 2 |  |  |  | 1.2 |  |  |  | 3 |
Exercise price US dollars |  |  | 4.5 |  |  |  | 4.5 |  |  |  | 4.5 |  |  |  | 4.5 |
Share price (US dollars) |  |  | 2.45 |  |  |  | 2.45 |  |  |  | 2.38 |  |  |  | 2.38 |
Fair value (US dollars) |  |  | 0.002 |  |  |  | 0.311 |  |  |  | 0.159 |  |  |  | 0.481 |

X
- Definition Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=igap_DerivativeWarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |